Systemic Atopy and Immunoglobulin Deficiency in Turkish Patients with Vernal Keratoconjunctivitis

Bozkurt, Banu; Artaç, Hasibe; Arslan, Nasha; Göktürk, Bahar; Bozkurt, Mete Kaan; Reisli, İsmail; İrkeç, Murat

doi:10.3109/09273948.2012.723110

Cited by 12 publications

(18 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Overall, 69.3% were males, and the mean age of patient was 9.8 years (range, [7][8][9][10][11][12][13][14][15][16][17][18][19]. There was no statistically significant difference between the two groups in terms of sex or mean age (p > 0.05).…”

Section: Resultsmentioning

confidence: 99%

“…Conventionally, VKC was considered primarily a type 1 hypersensitivity reaction. However, approximately 50% of the patients with VKC have no familial or personal history of atopy, and a large proportion have negative results on the Standard allergic diagnostic tests, confirming that it is not solely immunoglobulin E (IgE)-mediated [10]. Recent studies suggest a more complex non-IgE-dependent pathogenic mechanism.…”

mentioning

confidence: 99%

“…Th2-derived cytokines such as IL-4, IL-5, IL-13, growth factors and enzymes are found in the conjunctiva of VKC patients [11]. In addition, some researchers have demonstrated the possible involvement of neural factors, sex hormones and conjunctival histaminase deficiency in the pathogenesis of the disease [2,10,11].…”

mentioning

confidence: 99%

See 2 more Smart Citations

Topical Cyclosporine A 0.05% Eyedrops in the Treatment of Vernal Keratoconjunctivitis – Randomized Placebo-Controlled Trial

Keklíkçí¹,

Dursun²,

Cingü³

2014

Adv Clin Exp Med

View full text Add to dashboard Cite

Background. Vernal keratoconjunctivitis (VKC) is a chronic, bilateral inflammation of the conjunctiva that mostly affects children and young adult males. Management of VKC is primarily aimed at reducing symptoms and preventing serious vision threatening sequelae. Objectives. To assess the efficacy of topical cyclosporine A (CsA) 0.05% on the signs and symtomps in the management of VKC. Material and Methods. This is a placebo-controlled, randomized prospective study. Sixty-two patients with VKC were included in this study. Patients were randomly assigned (1 : 1) to treatment with topical 0.05% CsA eyedrops or a placebo (artificial tears) for a period of 4 weeks, 4 times daily. Ocular signs and symptoms were in all patients scored at entry and at the end of 4 weeks. Results. When pre-treatment mean signs and symptoms scores were compared in both groups, there was no significant difference (p > 0.05). However, mean post-treatment scores as regards signs and symptoms were found to be lower in cyclosporine group than those in placebo group (p < 0.001). No side effects of the treatment with CsA 0.05% eyedrops were observed. Conclusions. It was found that topical CsA 0.05% eyedrops were safe and effective in the treatment of patients with VKC (Adv Clin Exp Med 2014, 23, 3, 455-461).

show abstract

Section: Resultsmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Topical Cyclosporine A 0.05% Eyedrops in the Treatment of Vernal Keratoconjunctivitis – Randomized Placebo-Controlled Trial

Keklíkçí¹,

Dursun²,

Cingü³

2014

Adv Clin Exp Med

View full text Add to dashboard Cite

show abstract

“…Each patient gave written informed consent, assisted by a translator where appropriate, to participate in this study, to provide blood samples and demographic as well as clinical data. Participants aged [15][16][17][18] years gave written assent to be a participant and a parent or guardian gave written informed consent.…”

Section: Design and Subjectsmentioning

confidence: 99%

The Role of Hiv in the Pathogenesis of Adult-Onset Vernal Keratoconjunctivitis: A Demographic and Epidemiological Study

Kritzinger

Zaborowski

Sibanda

et al. 2019

Preprint

View full text Add to dashboard Cite

Background: Very few studies in the literature describe adult-onset vernal keratoconjunctivitis (VKC). HIV has many associated ocular pathologies and an association with VKC has not been described yet. The aim is to identify and describe patients who present with new-onset VKC after puberty, with no prior history of atopic diseases or allergies. Methods: The study consisted of two parts: the first part was a prospective observational descriptive study of patients with adult-onset VKC, detailing the epidemiological and demographic characteristics of these patients, including their HIV status. The second was a case-control study to determine the relationship of a CD4 count with adult-onset VKC in the setting of HIV. Patients were recruited between January 2016 and November 2017 from McCord Provincial Eye hospital, one of two large referral hospitals for the province of KwaZulu-Natal, South Africa. Patients presenting to the Eye clinic were screened at the Primary Eye Care Unit. Inclusion criteria were age 15 years and older with signs and symptoms of new-onset VKC. Exclusion criteria were a history of childhood atopic diseases, atopic keratoconjunctivitis and patients who refused HIV testing. Data collected included HIV status, CD4 count where appropriate, anti-nuclear antibodies and total serum immunoglobulin E. Results: 33 patients were included in this study; females n=16, males n=17. The mean age at presentation was 32.45±9.93 years, 95% CI=28.94-35.97. All of the patients were black Africans. One patient tested ANA positive. 51.5% of patients had a raised IgE level. A total of 13 of 25 HIV positive patients (52%) had a raised IgE. The proportion of HIV positive patients was statistically different from the HIV negative group, with Chi-squared = 21.866, p-value <0.0001. 72% of the HIV positive patients were grouped as immunodeficient according to their CD4 counts. An association was proven between severely immunodeficient patients and the risk of having VKC (chi-squared=4.992, p-value=0.0255). Conclusion: In this cohort a statistically significant association was found between adult-onset vernal keratoconjunctivitis and an HIV positive status. This association calls for more research on the subject, but could imply that patients presenting with adult-onset VKC should be offered an HIV test. Key words: Vernal keratoconjunctivitis, New-onset VKC Adult-onset VKC Ocular manifestations of HIV Allergy Immunocompromised.

show abstract

“…[3][4][5] Steroids are being used as the mainstay of treatment for VKC, but a standard treatment protocol is not yet established. Steroids are very effective in controlling the acute exacerbation, but they may cause intraocular pressure elevation in steroid-responders, risk of corneal infection, and cataract.…”

Section: Introductionmentioning

confidence: 99%

Comparative Study of 0.1% Olopatadine vs 0.05% Cyclosporine in Patients of Recalcitrant Vernal Keratoconjunctivitis

Gupta¹,

Goyal²,

Devendra³

2016

International Journal of Advanced and Integrated Medical Sciences

View full text Add to dashboard Cite

show abstract

Systemic Atopy and Immunoglobulin Deficiency in Turkish Patients with Vernal Keratoconjunctivitis

Abstract: IgE-mediated mechanisms are involved in approximately 40% of VKC patients. A new finding was the higher incidence of Ig deficiency.

Cited by 12 publications

References 37 publications

Topical Cyclosporine A 0.05% Eyedrops in the Treatment of Vernal Keratoconjunctivitis – Randomized Placebo-Controlled Trial

Topical Cyclosporine A 0.05% Eyedrops in the Treatment of Vernal Keratoconjunctivitis – Randomized Placebo-Controlled Trial

The Role of Hiv in the Pathogenesis of Adult-Onset Vernal Keratoconjunctivitis: A Demographic and Epidemiological Study

Comparative Study of 0.1% Olopatadine vs 0.05% Cyclosporine in Patients of Recalcitrant Vernal Keratoconjunctivitis

Contact Info

Product

Resources

About